Rafael Holdings, Inc. RFL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -8.47%
- 1 year
- -20.00%
- Open
- 1.15
- Prev close
- 1.12
- Mkt cap
- 56.36M
- Vol
- 67.24K
- Avg vol
- 145.08K
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.23
- Forward P/E
- 0.00
- Beta
- 1.07
- Short ratio
- 1.80
- Inst. own
- 10.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.90
- 200-d avg
- 1.68
- 1y target
- 0.00
News
3 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to…
-
4 days ago benzinga.com
Rafael Holdings Q4 EPS $(0.18) Up From $(0.28) YoY, Sales $244.000K Down From $350.000K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.18) per share. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported…
-
4 days ago benzinga.com
Rafael Holdings Files New Drug Application To FDA For Approval Of Remibetadex To Treat Neurovisceral Manifestations Of Niemann-Pick Disease Type C
Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking…
4 days ago globenewswire.com
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.
4 days ago globenewswire.com
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
NDA supported by the Phase 3 TransportNPC ™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls
5 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised…
1 month ago benzinga.com
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
1 month ago benzinga.com
Why Is Rafael Stock Falling Wednesday?
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
1 month ago benzinga.com
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The…
-
1 month ago benzinga.com
Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance
Trappsol® Cyclo™ was well tolerated and demonstrated a directionally favorable treatment effect on the primary endpoint, although the result did not achieve statistical significance. Notably, a…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
4 months ago benzinga.com
Rafael Holdings Q3 EPS $(0.08) Up From $(0.19) YoY, Sales $179.000K Down From $362.000K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.08) per share. This is a 57.89 percent increase over losses of $(0.19) per share from the same period last year. The company reported…
-
4 months ago benzinga.com
Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026
The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026The company has received acknowledgement from the FDA that our US Expanded Access…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
Rafael Holdings' Cyclo Therapeutics Enters Into Exclusive Licensing Agreement With MIT For Small Molecules To Improve Myelination In Apoe4 Positive Alzheimer's Disease
Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology ("MIT") covering…
-
7 months ago benzinga.com
Rafael Holdings Q2 EPS $(0.13) Up From $(0.19) YoY, Sales $211.000K Up From $77.000K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year. The company reported…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
Rafael Holdings Q3 EPS $(0.19) Up From $(1.36) YoY, Sales $362.00K Up From $336.00K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 86.03 percent increase over losses of $(1.36) per share from the same period last year. The company reported…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
Rafael Holdings Updates Terms Of Rights Offering, Granting 1 Non-Transferable Subscription Right Per Share Or Equivalent Public Warrant Held As Of May 9, 2025, Allowing Holders To Purchase 0.603 Shares Of Class B Common Stock At $1.28 Per Share, With Public Warrant Holders Receiving 0.3525 Rights Per Warrant And Full Rights Granted Per 3 Warrants Held
Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering.Under the…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
Rafael Holdings Revises Subscription Rights Following Prior $25M Rights Offering To Support Development And Potential Launch Of Trappsol Cyclo
Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering.Holders of record as of May 9, 2025 (the "Record…
-
1 year ago benzinga.com
Rafael Holdings Announces Proposed Terms Of $25M Rights Offering To Support Its Commitment To Development And Potential Launch Of Trappsol Cyclo.
Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our…
-
1 year ago benzinga.com
Rafael Holdings Q4 EPS $(0.19) Down From $0.06 YoY, Sales $165.00K Up From $68.00K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 416.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported…
-
2 years ago benzinga.com
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Rafael And Cyclo Therapeutics Have Agreed To Combine To Focus Trappsol Cyclo For Niemann-pick Disease Type C1
On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings…
-
3 years ago benzinga.com
Rafael Holdings Q4 EPS $0.06 Up From $(0.24) YoY, Sales $68.00K Down From $69.00K YoY
Rafael Holdings (NYSE:RFL) reported quarterly earnings of $0.06 per share. This is a 125 percent increase over losses of $(0.24) per share from the same period last year. The company reported $68.00…
-
3 years ago benzinga.com
Cyclo Therapeutics Ended The Quarter With ~$0.8M Of Cash. Subsequent To Quarter-End, The Company Generated Gross Proceeds Of $5M From The Sale Of Securities In Private Placements Of The Co's Securities
Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end
-
3 years ago benzinga.com
Rafael Holdings Q3 EPS $(0.06) Up From $(0.28) YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.06) per share. This is a 78.57 percent increase over losses of $(0.28) per share from the same period last year.
-
3 years ago benzinga.com
Rafael Holdings Announces Up To $5M Share Repurchase Program
Rafael Holdings, Inc. (NYSE:RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. "We remain committed to
-
3 years ago benzinga.com
Rafael Holdings Q2 EPS $(0.14) Down From $(0.12) YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.14) per share. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.
-
3 years ago benzinga.com
Top Real Estate Stocks That May Plunge
The most overbought stocks in the real estate sector presents an opportunity to go short on these overvalued companies.
-
3 years ago benzinga.com
Rafael Holdings Q1 EPS $(0.22) Up From $(0.75) YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.22) per share. This is a 70.67 percent increase over losses of $(0.75) per share from the same period last year.
-
3 years ago benzinga.com
Rafael Holdings To Focus On Strategic Business Development Initiatives And Curtail Early Stage Development Activities; As Of July 31, 2022, The Company Held Cash, Cash Equivalents And Marketable Securities Of $63.2M
Rafael Holdings, Inc. (NYSE:RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spending and…
-
4 years ago benzinga.com
Rafael Holdings Q4 EPS $(0.24) Up From $(0.75) YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.24) per share. This is a 68 percent increase over losses of $(0.75) per share from the same period last year.
-
4 years ago benzinga.com
Cornerstone Pharmaceuticals Announces Successful Completion Of Phase 1b Clinical Trial For CPI-613 In Combination With Gemcitabine And Cisplatin In Patients With Biliary Tract Cancer
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful